To include your compound in the COVID-19 Resource Center, submit it here.

Aganocide compound: Phase II data

A double-blind, U.S. Phase II trial in 81 evaluable patients with confirmed adenoviral conjunctivitis showed that NVC-422 ophthalmic solution given 8 times daily for 10 days missed the primary endpoint of a 20% greater sustained microbiological success rate for eradication of adenoviruses compared

Read the full 430 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers